NCT06286150Recruiting
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery: A Prospective, Single Center Study
Source: ClinicalTrials.gov · Last updated 29 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Robotic surgical systems have become a promising surgical assistance system, with unique advantages such as 3D high-definition visual system, highly flexible wrist-jointed instruments, and automatic fitering of hand tremors. Robotic surgical systems is applied in various fields including urology, general surgery, cardiothoracic surgery, head and neck surgery, and gynecology. Currently, the Da Vinci surgical robot system is the most widely used robot system globally. However, the Da Vinci robot system for single-port laparoscopic surgery has not yet been launched in China. Therefore, the investigators conduct a prespective, single-center study to evaluate the efficacy and safety of single-port surgical robot system in thoracic surgery.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 15 Feb 2024
- Start date
- 15 Sept 2023
- Primary completion date
- 15 Jul 2025
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT06286150
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 15 Sept 2023 to the primary completion date, 15 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a suspected or confirmed alcohol, drug, or substance addiction.
- Participation in other interventional clinical trials within 3 months prior to signing the informed consent form.
Other illness
- Patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator.
- Patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery.
- Patients with severe bleeding tendencies or coagulation disorders.
- Patients in the active phase of infectious diseases or with other severe non-communicable infections.
- Patients positive for Human Immunodeficiency Virus (HIV) antibodies or syphilis seropositive patients.
- Patients with a history of epilepsy, mental illness, or cognitive impairment.
Other
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.
- Other situations in which the investigator deems inappropriate for participation in this clinical trial.
Who the study is looking for
- Age between 18 and 75 years, regardless of gender.
- Patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery.
- Preoperative ASA classification of I-III.
- Voluntary participation in the clinical trial and willingness to provide informed.
- consent, either by the subject or their guardian.
- Willingness to cooperate and complete trial follow-up and related examinations.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.